The Impact of MRI-Defined Extent of Resection Across Meningioma DNA Methylation Groups: Re-Evaluating Surgery in the Era of Meningioma Molecular Classification

Ramin A Morshed; Minh P Nguyen; Abrar Choudhury; Nadeem N Al-Adli; Stephen T Magill; Alexander F Haddad; Kanish Mirchia; Calixto-Hope G Lucas; Philip V Theodosopoulos; Michael W McDermott; William C Chen; David R Raleigh

doi:10.1227/neu.0000000000003324

The Impact of MRI-Defined Extent of Resection Across Meningioma DNA Methylation Groups: Re-Evaluating Surgery in the Era of Meningioma Molecular Classification

Neurosurgery. 2025 Jan 7. doi: 10.1227/neu.0000000000003324. Online ahead of print.

Authors

Ramin A Morshed¹, Minh P Nguyen^{1

2

3}, Abrar Choudhury⁴, Nadeem N Al-Adli¹, Stephen T Magill⁵, Alexander F Haddad¹, Kanish Mirchia³, Calixto-Hope G Lucas^{6

7

8}, Philip V Theodosopoulos¹, Michael W McDermott^{1

9}, William C Chen², David R Raleigh^{1

2

3}

Affiliations

¹ Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
² Department of Radiation Oncology, University of California, San Francisco, San Francisco, California, USA.
³ Department of Pathology, University of California, San Francisco, San Francisco, California, USA.
⁴ Department of Radiation Oncology, Harvard University, Boston, Massachusetts, USA.
⁵ Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USA.
⁶ Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
⁷ Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USA.
⁸ Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
⁹ Miami Neuroscience Institute, Baptist Health of South Florida, Miami, Florida, USA.

PMID: 39773932
DOI: 10.1227/neu.0000000000003324

Abstract

Background and objectives: Extent of resection (EOR) is prognostic for meningioma outcomes. DNA methylation profiling can shed light on biological drivers and therapeutic vulnerabilities. The goal of this study was to re-evaluate the impact of EOR on clinical outcomes across meningioma DNA methylation groups.

Methods: Patients with sporadic meningiomas who underwent resection from a multicenter, international cohort were retrospectively reviewed. Gross vs subtotal resection (GTR vs STR, respectively) was determined based on postoperative MRI. The Kaplan-Meier method, log-rank statistics, and multivariable Cox proportional hazard analyses were performed to evaluate the impact of EOR on local freedom from recurrence (LFFR) and overall survival (OS).

Results: In total, 587 patients (Male: 195, Female: 392) underwent 644 surgeries for intracranial meningioma (GTR: 438, STR: 206), with 124 surgeries (19.3%) for recurrent intracranial meningiomas. The cohort included 375 (58.2%) World Health Organization (WHO) Grade 1, 202 (31.4%) WHO Grade 2, and 67 (10.4%) WHO Grade 3 meningiomas based on histological criteria. DNA methylation profiling was used to categorize meningiomas as Merlin-intact (N = 214, 33.2%), Immune-enriched (N = 236, 36.6%), or Hypermitotic (N = 194, 30.1%). GTR was associated with longer LFFR across all meningioma DNA methylation groups (Merlin-intact P < .0001; Immune-enriched P = .013; Hypermitotic P = .001) and was associated with longer OS for Hypermitotic meningiomas (P = .0022). In multivariable Cox proportional hazard analyses, EOR was significantly associated with LFFR across all DNA methylation groups and WHO grades but was significantly associated with OS only for Hypermitotic meningiomas (hazard ratio [GTR vs STR] 0.64, 95% CI 0.43-0.97, P = .034).

Conclusion: MRI-defined GTR is associated with improved LFFR across all meningioma DNA methylation groups and improved OS for patients with Hypermitotic meningiomas. These data continue to support maximal safe resection when feasible and demonstrate how molecular classification systems complement rather than supersede the prognostic impact of surgery.